AT
GILD icon

Arlington Trust’s Gilead Sciences GILD Stock Holding History

Arlington Trust’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8K Buy
212
+37
+21% +$4.88K ﹤0.01% 353
2026
Q1 		$24.4K Buy
175
+74
+73% +$10.4K ﹤0.01% 312
2025
Q4 		$12.4K Buy
+101
New +$12.3K ﹤0.01% 291
2025
Q3 		– Sell
-155
Closed -$17.2K – 623
2025
Q2 		$17.2K Buy
155
+5
+3% +$532 ﹤0.01% 456
2025
Q1 		$16.8K Sell
150
-47
-24% -$4.85K ﹤0.01% 473
2024
Q4 		$18.2K Buy
197
+47
+31% +$4.23K ﹤0.01% 425
2024
Q3 		$12.6K Sell
150
-86
-36% -$6.56K ﹤0.01% 437
2024
Q2 		$16.2K Sell
236
-150
-39% -$10K ﹤0.01% 416
2024
Q1 		$28.3K Sell
386
-173
-31% -$13.3K 0.01% 314
2023
Q4 		$45.3K Buy
559
+536
+2,330% +$41.7K 0.01% 292
2023
Q3 		$1.72K Buy
+23
New +$1.77K ﹤0.01% 280

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arlington Trust's GILD Position: Q2 2026 in Review

Arlington Trust increased its Gilead Sciences (GILD) stake by 21% in Q2 2026, buying an estimated $4.88K and bringing the position to 212 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Arlington Trust first reported a position in GILD in Q3 2023 and has held it in 11 quarters since. The position peaked at $45.3K in Q4 2023. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Arlington Trust held 212 shares of Gilead Sciences worth $26.8K as of Q2 2026.
  • Arlington Trust bought 37 Gilead Sciences shares in Q2 2026, an estimated $4.88K.
  • Gilead Sciences made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #353 holding.
  • Arlington Trust first reported a position in Gilead Sciences in Q3 2023 and has held it in 11 quarters since.
  • Arlington Trust's Gilead Sciences position peaked at $45.3K in Q4 2023.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.